Aleva Neurotherapeutics has developed proprietary neurostimulation technologies that enable significantly better therapies for neurological diseases. Deep Brain Stimulation (DBS) therapy, used in indications including Parkinsonʼs Disease, is an existing market growing at over 15% annually and is Alevaʼs first target market. With Alevaʼs microDBS products, neurosurgeons and neurologists will see reduced surgical and follow-up times, patients will benefit from a decrease in debilitating side effects, and payers will see a substantial reduction in cost-of-care.
Alevaʼs microDBS Technology can significantly reduce the overall cost of a DBS procedure while nearly eliminating the complications and side effects associated with the therapy.
ALEVA NEUROTHERAPEUTICS SA | PARC SCIENTIFIQUE - BATIMENT D | EPFL | 1015 LAUSANNE | SWITZERLAND | +41 21 693 87 64 | INFO@ALEVA-NEURO.COM